The US Food and Drug Administration (FDA) approved oral daily tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis of human immunodeficiency virus (HIV) infection in 2012 on the basis of two randomized controlled trials (RCTs), one in men who have sex with men (MSM) and another in HIV serodiscordant heterosexual couples. Subsequently, even greater efficacy has been demonstrated in MSM with rapid population-level incidence reductions in some locations. In contrast, studies of antiretroviral pre-exposure prophylaxis (PrEP) in heterosexual women showed only modest or no efficacy, largely attributed to low adherence. The mixed results of antiretroviralbased PrEP bear witness to unique drug development challenges at this complicated intersection of sexual behavior, public health, and drug development. Multiple innovative methods and formulation strategies followed to address unmet medical needs of persons struggling with daily oral PrEP adherence or preference for nonsystemic PrEP options. Clinical pharmacology plays essential roles throughout this PrEP development process, especially in early product development and through pharmacologically informed enhancement and interpretation of clinical trials.
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PRE-EXPOSURE PROPHYLAXIS NEED AND IMPACT
The global human immunodeficiency virus (HIV) pandemic peaked in the last decade with recent 2% annual declines in HIV incidence in adults, attributed to changes in risk-taking behavior, increased HIV testing and treatment, implementation of male circumcision, and pre-exposure prophylaxis (PrEP) with antiretroviral (ARV) drugs ( Figure 1) . However, ~1.8 million new infections still occur globally each year-5 thousand daily-40 thousand in the United States. 1, 2 This heterogeneous epidemic shows increasing rates of HIV infection in several subpopulations. In the United States, for example, black and Hispanic men who have sex with men (MSM) have experienced 4% and 14% increases, respectively, in HIV infection recently, especially in southern states. In contrast, nearly half (43%) of new infections globally occur in eastern and southern Africa where women and girls account for 6 of 10 existing HIV infections. A great unmet medical need persists for HIV prevention methods in diverse populations at risk.
PrEP uses oral, topical, or systemically applied ARV drugs before sex or injection drug use to prevent HIV. The HIV microbicides are a subset of PrEP strategies applied topically to the vagina or rectum. Providing the receptive sexual partner with control over one's own HIV protection is a key motivation for PrEP. A substantial PrEP research and development effort has been funded by the United States and other governments, the Bill and Melinda Gates Foundation, and many other donors. Academic scientists, in close collaboration with and funded almost exclusively by these noncommercial funders, successfully repurposed an oral HIV treatment product for PrEP (fixed dose tenofovir (TFV) disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg), advanced TDF/FTC implementation in numerous demonstration projects, brought a dapivirine (DPV) intravaginal ring (IVR) to European Medicines Agency (EMA) review, and continue to advance several dozen PrEP products to enable a broader range of product options. Although there has been essential collaboration with Big Pharma in ARV PrEP development for more than 15 years, this has not included funding or leadership of any large pivotal clinical trial until current second generation PrEP comparison studies.
In 2011, Gilead submitted to the US Food and Drug Administration (FDA) their supplemental new drug application package supporting once daily oral TDF/FTC (Truvada) for HIV prevention, which included two randomized controlled trials (RCTs) of PrEP efficacy: iPrEx (National Institutes of Health and Gates funded) and Partners PrEP (National Institutes of Health funded; Table 1 ). TDF (2001), FTC (2003) , and the fixed dose TDF/FTC combination (2004) had been approved earlier for HIV treatment. The FDA approved the submission in 2012 for adults and for adolescents greater than 35 kg in 2018. Regulatory bodies in at least 25 countries have approved TDF/FTC for use as PrEP. At least three generic formulations have been approved by the FDA. The package insert recommends TDF/FTC in combination with other safer sex practices in adults and adolescents at "high risk" of HIV infection. The Centers for Disease Control and Prevention (CDC) recommended TDF/FTC as PrEP as one prevention option for sexually active adults and persons who STATE of the ART inject drugs (not in the FDA label) at "substantial risk" for HIV acquisition (defined in detail). The World Health Organization recommends TDF/FTC for persons at "substantial risk" of HIV infection (including persons who inject drugs) defined as groups with > 3% HIV incidence.
PrEP uptake in the United States remained at very low levels through 2014, but rose substantially through 2018. Demonstration projects describe the successful implementation of TDF/FTC PrEP in many locations globally, largely in communities of MSM and transgender women (TGW). In San Francisco, new infections dropped by 51% from 2012-2016 largely attributed to PrEP implementation. 3 In Australia, the Expanded PrEP Implementation in Communities in New South Wales (EPIC-NSW) study recorded only two HIV infections in 3,927 person-years (0.05% incidence vs. a historical 2%) in MSM with an associated population level 32% fall in incidence over the period of the 2-year study. 4, 5 The estimated number needed to treat (NNT) with PrEP to prevent one HIV infection from sex ranges from 13-100 overall among the primary PrEP RCTs ( Table 1) . For context, the NNT for use of statins or antihypertensive medications in persons with unknown heart disease to prevent stroke and myocardial infarction over 5 years ranges from 67-157. 6 Most US insurance companies and government payers (Medicaid, Veterans Affairs, and the Department of Defense) support PrEP to some degree.
UNDERSTANDING HETEROGENEOUS PREP OUTCOMES
The first RCTs of ARV HIV PrEP concluded within months of each other in early 2010: CAPRISA 004, a study of an on-demand TFV vaginal gel in South African women and the pre-exposure prophylaxis initiative (iPrEx), a study of oral daily TDF/FTC in MSM and TGW (Table 1) . 7, 8 These very different strategies and study populations demonstrated modest efficacy, 39% and 44%, respectively. Future trial success of oral TDF/FTC regimens diverged along the lines of study populations: increasingly greater success in studies of MSM, TGW, and serodiscordant couples, 9, 10 but modest or no efficacy in several studies of oral and vaginal formulations in heterosexual women. [11] [12] [13] [14] [15] The HIV prevention outcomes tightly aligned with detection of TFV and FTC in blood or cervicovaginal fluid. Modeling pharmacokinetic (PK) data from within and across PrEP RCTs with pharmacodynamic (PD) seroconversion end points indicates clear TFV concentration-HIV protection response relationships. 16, 17 These model results do not take into account the presence of FTC in the PrEP regimens when estimating the TFV effective concentration 90% (EC 90 ), therefore, these TFV EC 90 results are only relevant when FTC is also in the dosing regimen as it almost always is in oral dosing studies, but not as commonly in topical studies. Estimating the EC 90 for each drug independently, resulting in higher EC 90 estimates for TFV-DP, has been done in more recent bottom-up mechanistic modeling and empiric mouse dose-ranging drug combination studies. 18, 19 Numerous small PK studies enabled interpretation of very wide concentration heterogeneity across trials as due largely to variable adherence, different PK in vaginal vs. rectal tissue, and changes in the vaginal microbiome. Numerous other variables are discussed later.
Adherence vs. PK variation
Adherence explains most variation among study outcomes, proving so influential in iPrEx and Partners PrEP that the FDA emphasized the importance of adherence in the TDF/FTC label revised to add the PrEP indication. Pre-observed and post-observed dose PK sampling enabled pharmacometric analyses to tease apart the relative contribution of adherence separate from PK variation. 20 Directly observed dosing studies simulated a range of adherence patterns (daily to weekly) in a variety of matrices (plasma, peripheral blood mononuclear cells (PBMCs), dried blood spots, and hair) to provide adherence benchmarks for quantitative interpretation of HIV outcomes and adherence covariates. [21] [22] [23] These benchmarks were also used for ongoing quantitative adherence assessment in several trials to target adherence interventions. 24, 25 These tools are widely used to assess adherence in PrEP demonstration projects and clinical practice. Electronic monitoring system data from the Partners PrEP trial informed Markov-chain Figure 1 Human immunodeficiency virus (HIV) prevention methods include strategies to reduce the infectious burden in the infected partner and reduce susceptibility in the uninfected "at risk" partner. Pre-exposure prophylaxis is one of many highly effective methods to reduce HIV infection working in a complementary manner with these other prevention methods. STI, sexually transmitted infection. Multiple groups have reported substantial cervicovaginal vs. colorectal differences in tissue PK of the active form of TFV (TFV diphosphate (TFV-DP)) and FTC (FTC triphosphate (FTC-TP)) and deoxynucleotide triphosphates (dNTP), dATP, and dCTP, respectively, the natural competitors of nucleoside reverse transcriptase inhibitor (NRTIs) for HIV reverse transcriptase. 27, 28 A complex PK picture emerges indicating an important role for both drugs in both anatomic locations, more rapid phosphorylation and clearance of FTC than TFV, 10 to 100-fold higher concentrations of the active TFV-DP in colorectal tissue and 100-fold higher active FTC-TP in cervicovaginal tissue, and 10-fold lower dNTP concentrations in colorectal tissue. Although there are competing methods for incorporation of the dNTP data into complex PK-viral dynamics models of these interactions, 18, 27, 28 the data help explain the need for at least 6-7 weekly doses of TDF/FTC in women (whose primary risk is receptive vaginal intercourse (RVI)), less frequent 4 per week dosing in MSM and TGW (whose primary risk is receptive anal intercourse (RAI)), and how only a few doses seems to provide rapid protection in MSM and TGW as in Ipergay. 15 Another source of PK variability is that the specific intracellular kinases that phosphorylate TFV and FTC vary anatomically among the cells in blood, cervicovaginal tissue, and colorectal tissue; the kinases are also genetically polymorphic.
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Vaginal microbiome and genital inflammation An abnormal nonlactobacillus dominant vaginal microbiome was associated with reduced cervicovaginal lavage fluid (CVL) and plasma TFV concentrations in different studies, as well as a threefold reduction in HIV protection in the CAPRISA 004 study of TFV vaginal gel. 32, 33 Some post hoc analysis concerns were allayed by finding nonlactobacillus dominant microbiome in similar proportions of high and low adherence groups and both TFV and placebo arms. These changes were not seen with oral TDF/FTC dosing or vaginal dosing of DPV, although there may be other microbiome impacts on DPV. [34] [35] [36] Bacteria possess a variety of enzymatic mechanisms for drug metabolism, including hydrolases, oxidoreductases, lyases, and transferases with established impact on dozens of licensed drugs. 37 Genital inflammation, defined by the presence of pro-inflammatory cytokines in CVL, was associated with no protective benefit of TFV gel in the CAPRISA 004 study compared to a 75% relative risk reduction in women without genital inflammation. 38 These findings indicate a need for prospective assessment of microbial metabolism of PrEP drug candidates, reassessment of drug concentration-based adherence measures in trials of topical drugs, and consideration of inflammation as an explanatory variable in future clinical trials.
UNIQUE PREP DEVELOPMENT CHALLENGES
Despite the RCT proven efficacy and population level impact of oral TDF/FTC PrEP, there remains a substantial demand for alternative PrEP methods. Some acceptability assessments indicate one-quarter of persons at risk prefer on-demand, coitally related dosing to daily dosing. 25, [39] [40] [41] Long-acting formulations (e.g., the DPV IVR) frees users from the challenges of sustaining daily pilltaking behavior. On demand formulations (e.g., Ipergay pericoital dosing) link PrEP to the time of risk. Behaviorally congruent formulations add ARVs to products that are commonly used before sex (e.g., sexual lubricants and douches). Choice among PrEP options should increase overall HIV prevention just as contraceptive choice increased contraceptive effectiveness. 42, 43 Continued PrEP product development to expand product choice is complicated by the convergence of numerous challenging obstacles ( Table 2) . Most of all, the inability to assess concentration response for HIV prevention in a traditional phase II proof-of-concept study greatly hinders product development requiring reliance upon imperfect preclinical and ex vivo surrogates. Development of chemoprevention for some infectious diseases can use clinical challenge studies to provide proof-of-concept, for example, as can be done with prevention of malaria using treatable parasite challenge study designs. 44 Pharmacology and virology knowledge have grown substantially during the PrEP development decades, but fundamental PrEP product development questions about site of entry, the timing and location of early infectious events, and persistence of infectious virions remain unanswered. The inability to quantitatively monitor sexual exposures in order to link risk exposure to dosing events hinders our understanding of relationships among HIV risk, drug exposure, and protective response.
Given the unique development challenges, the unproven status of PrEP as an HIV prevention strategy, and the mismatch between the unmet medical need and financial ability to afford PrEP, investing in PrEP drug development was a very high-risk endeavor until the last few years. Likely for these reasons, large pharmaceutical companies watched PrEP trials encouragingly, but largely, from the sidelines. Now that governments and philanthropy have greatly derisked PrEP by funding numerous studies proving PrEP ARV efficacy in diverse populations and funding high impact implementation projects, large pharmaceutical companies are entering the playing field with greater energy and funding. Gilead's ongoing DISCOVER trial compares two Gilead products, TDF/FTC vs. TAF/FTC, and is the first RCT funded fully by a large pharmaceutical company. ViiV/GSK is also an important funding partner in HIV Prevention Trial Network (HPTN) studies. Hopefully, the substantial progress in surmounting the complex PrEP development hurdles (discussed below) encourages and informs both greater industry engagement and continued governmentphilanthropic-industry collaboration to improve PrEP choices.
Proof-of-concept alternatives
In the ARV treatment setting, proof-of-concept requires only a few dozen HIV-infected persons in brief 1-2 week multiple ascending dose studies providing concentration-response data to greatly reduce the risk and uncertainty of performing pivotal RCTs in hundreds of patients with HIV later. By contrast, PrEP development lacks clinical concentration-response options in phase II studies that would ordinarily encourage and guide regimen selection for phase III studies. Further complicating trial designs, because HIV incidence rates in the RCT study populations were below 10%, over 90% of phase III research participants are not contributing to event comparisons, thus requiring sample sizes in the thousands (Table 1) . Now in the age of head-to-head RCTs (DISCOVER, HPTN 083, HPTN 084, and AMP studies) with active control arms having much smaller incidence, RCT sample sizes are ballooning to many thousands and quarter billion dollar price tags. Of necessity, new methods were developed to advance pharmacometric modeling and viral challenge models with animals and ex vivo human cervicovaginal and colorectal mucosal tissue. In the early years of PrEP development, these surrogate methods were often explored only in parallel with RCTs, but have been used more recently to inform product design earlier in development ( Table 3) .
Pharmacokinetic method development
Enhancing pharmacokinetic methods. From the earlier HIV treatment development programs, repurposed ARVs for PrEP began development armed with historical data on PK in blood elements. The analytical efforts supporting the PK/ PD assessments of the primary PrEP clinical RCTs ( Table  1) were performed at five academic laboratories: Kashuba at UNC-Chapel Hill (CAPRISA 004, FEM-PrEP, and FACTS 001 trials), Anderson at University of Colorado (iPrEx and Ipergay), Bumpus at Johns Hopkins (Partners PrEP, TDF2, Bangkok TFV studies), Marzinke at Johns Hopkins (VOICE, ASPIRE, and Ring studies), and Khoo at University of Liverpool (PROUD study). Laboratory quality is high as all of these laboratories participate in one of two ongoing assay quality review programs with proficiency testing and cross-validation work between the two quality review programs. 45, 46 Methods for assessing the female genital tract (Kashuba) and intracellular pharmacology (Anderson) predated PrEP development, but colorectal pharmacology methods were still needed to address PrEP-relevant mucosal pharmacology. Methods were developed to simultaneously assess intracellular dNTPs with active NRTIs and to perform tissue CD4+ T cell subset isolation. 28, [47] [48] [49] [50] [51] [52] Mucosal PK studies, limited to only a few timed biopsies per research participant, sometimes with near simultaneous cervicovaginal and colorectal biopsies, required sparse sampling designs and posed challenges recruiting healthy volunteers. 49, 51, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] These studies helped tremendously to explain the differences between protecting individuals during vaginal sex when compared to anal sex and were essential for rational alternative formulation development.
Pharmacokinetic-viral dynamic response modeling. Using clinical data, Cottrell (UNC) and Chen (Colorado), separately, developed pharmacometric models that aligned well with RCT outcomes. 27, 28 The one narrow exception to this alignment is underpredicting the high degree of success of oral TDF alone in women in Partners PrEP-71% in the intent-to-treat analysis and 100% in their nested adherence enhancement substudy. 9, 63 In parallel with the above clinical PK sampling efforts, Duwal, von Kleist, and colleagues at Freie Universität Berlin, have continued to evolve top-down and bottom-up molecular mechanism of action models, which correctly predicted later empiric intracellular PK work and their evolving models increasing the alignment with RCT outcomes as additional empiric data became available. 18, 64, 65 They also note the complementary roles of TDF and FTC in PrEP, although they propose alternative molecular models for incorporation of dNTP data to account for nonlinear and saturable relationships that differ between dATP/TFV-DP and dCTP/FTC-TP pairs. Their models address important virologic variables affecting PrEP efficacy (e.g., seminal viral load) and provide a rich modular framework readily usable for much needed clinical trial simulations to optimize future trial design of emerging PrEP candidates. Most of the above modeling has been focused on oral dosing with some assumptions about PBMC vs. tissue cell differences. Given the wealth of topical PrEP development innovations (see below), models to inform their development are badly needed.
Luminal drug and viral kinetics. For topical PrEP drug development, quantitative methods were developed to assess distribution of drugs and viral surrogates within the female genital tract and distal colon to insure ARV distribution in space and time matched or exceeded that of HIV surrogates. Barnhart and Pretorius (University of Pennsylvania) used magnetic resonance imaging (MRI) in the first microbicide distribution studies. 66 Our group built on his work and prior nuclear medicine methods in using single photon emission computed tomography/ computed tomography (SPECT/CT) to describe the distribution of substances applied to the vagina or rectum, including cell-free and cell-associated HIV surrogates after simulated vaginal and anal sex to identify the luminal distribution of interest for microbicides. [67] [68] [69] [70] We also dosed radiolabeled candidate microbicides followed by a radiolabeled HIV surrogate to assure the coincident distribution of microbicide and HIV target within the distal colon, which demonstrated the suitability of enema formulations, and raised concerns about the feasibility of delivering adequate intraluminal microbicide gel when applied as an anal lubricant. 59 Nonclinical viral challenge models.
In the absence of clinical surrogates of protection, macaque, mouse, and ex vivo human challenge models evolved during this period of PrEP development to enable more robust testing of candidates to guide clinical development ( Table 3 ; described in Data S1). All of these methods have put forward half-maximal effective concentration or EC 90 estimates to compare with clinical trial results as a type of validation. One feature of all these methods, both a necessity and a limitation, is that the challenge (ranging from 1-20 weekly occurrences) is designed to achieve 100% infection to minimize both time to infection and sample size. In reality, the riskiest sexual behavior, unprotected RAI, has a much lower estimated HIV infection risk per exposure of only 1 in 72 (CDC).
Vaginal product underperformance
Adherence incompletely explains PrEP outcomes. Correcting for adherence in the VOICE gel arm, protection increased to between 60% and 88% relative risk reduction in analyses by Dai (Poisson model, adherence defined as detectable plasma TFV ever or at 3 months) and Ruberman (targeted maximum likelihood estimation method, adherence defined as detectable plasma TFV at all observations). 74, 75 On demand dosing of the same gel in CAPRISA 004 showed 73% protection when adherence was high. 76 ASPIRE DPV IVR adherence adjustments increased the relative risk reduction estimate as high as 65% (using residual ring DPV concentration). 77 Although far better than the planned intentto-treat findings of low or no protection in these studies, these adherence-adjusted estimates fall short of the 100% relative risk reduction in the enhanced adherence cohort of Partners PrEP ( Table 1) . 63 Additional causes need to be identified to enable development of more effective vaginal products or study designs.
Poor rectal ARV penetration. Daily vaginal dosing of the TFV 1% gel achieved very low TFV-DP concentrations in rectal tissue, detectable in only 15% of women (27 fmol/mg lower limit of quantification), indicating concentrations well below simultaneous vaginal tissue concentrations (166 fmol/mg). 78 These rectal tissue concentrations after vaginal dosing predict very low, if any, protection from RAI for women using these vaginal products. Because RAI carries a much greater HIV transmission risk per exposure (e.g., 20-fold as a midpoint of numerous estimates), only one anal exposure among 20 total sexual exposures (5%) reduces the efficacy ceiling to only 50% protection in a vaginal microbicide trial. One anal exposure among 50 sexual exposures (only 2%) still drops the efficacy ceiling to 87%. Although data in RCTs does not have sufficient granularity to estimate RAI frequency among all sexual exposures, the percent of women practicing RAI during these RCTs can range up into double digits. Perhaps worse, if a woman anticipated RAI and thought to apply the TFV gel rectally, loss of colorectal epithelial integrity due to the hyperosmolar gel could result in an increased risk of HIV infection. 79 In contrast to TFV and DPV, a multidrug pod-IVR demonstrated emtricitabine and maraviroc colorectal tissue concentrations greater than the in vitro protein-adjusted IC 90 in women. 80 Other ARVs in development may also diffuse more efficiently into vaginal and rectal tissue, potentially providing protection for the vagina and rectum with application of a vaginal product. Another alternative would be to develop a product suitable for dosing in both the vagina and the rectum to provide women the flexibility of protecting themselves wherever needed. For this purpose, as noted, the TFV vaginal gel used in RCTs is not suitable for rectal dosing due to hyperosmolarity and gastrointestinal (GI) side effects. 51 Rectal DPV gel studies, used as a sexual lubricant and with an applicator, are ongoing (MTN-026 and MTN-033 studies).
Microbiome.
The previously discussed nonlactobacillus dominant microbiome effect on TFV gel efficacy, but not oral TDF efficacy, indicates an opportunity to improve TFV gel efficacy through treatment of bacterial vaginosis. 32, 34, 36 In addition, the impact of bacterial vaginosis on TFV indicates that plasma TFV-based adherence estimates in VOICE, as in CAPRISA 004, are underestimates depending on the frequency of women with nonlactobacillus dominant microbiome, often near 50%. Microbiome surveillance, both vaginal and rectal, is warranted in future microbicide product development.
Toxicity. Vaginal product trades off benefits of avoiding systemic toxicity and on-demand use with potential mucosal toxicity given high cervicovaginal concentrations. With a narrow therapeutic window, high levels of adherence may, paradoxically, see reduced protection. Many clinical toxicity measures have been used including visual examination, colposcopy, and mucosal permeability assessment, as well as assays of cytokines, methylthiazol tetrazolium tissue viability, and various "omics measures" among others. The challenge is correlating postdose changes in these tests with actionable toxicity requiring dropping a product or reducing a dose.
One might define actionable toxicity simply by two criteria: (1) clinically impactful changes, e.g., symptoms sufficient to reduce adherence; or (2) changes insufficiently high to counterbalance highlevel HIV protection. Recently, 8 of 12 women randomized to the active, but not placebo, arm of a TDF IVR developed vaginal erosions, symptomatic in half the women. 81 This presents a clear case for halting development of the product (and increased scrutiny of related products) given our simple rejection criteria of symptoms or offsetting HIV transmission risk. Nonoxynol-9, cellulose sulfate, and Pro2000 all had in vitro safety signals during development or coincident with their respective clinical trials, although of uncertain clinical significance at the time. [82] [83] [84] Nonoxynol-9 and cellulose sulfate increased HIV infection and Pro 2000 provided no protection when advanced to clinical trials, providing helpful, if retrospective and indirect, validation of in vitro toxicity tests. [85] [86] [87] [88] The current challenge is deciding when to halt development as unproven tests return abnormal results (e.g., proteomic or metabolomic changes), without the benefit of clinical evidence to validate the predictive value of candidate safety markers.
For rectal microbicides (discussed later) there are still no efficacy trial results to inform the validity of theoretical toxicity markers. Theoretically, colorectal tissue is highly vulnerable to toxicity because the single columnar epithelium is both more fragile and less thick a physical barrier when compared to the stratified squamous epithelium lining the vast majority of the exposed mucosal surfaces in the lower female genital tract. Before HIV-specific ARVs were studied, rectal dosing of hyperosmolar, N9-containing spermicides (e.g., K-YPlus, ForPlay, and Advantage 24) as well as hyperosmolar, nonmedicated sexual lubricants (e.g., Replens and ID Glide) resulted in epithelial cell exfoliation within 15-90 minutes after dosing and still notable 12 hours after dosing 79, 89, 90 ; some products were also associated with GI symptoms. Vaginal use of these same products and rectal use of nonmedicated, iso-osmolar gels (appropriate negative controls) were not associated with these histological findings or symptoms, consistent with the theoretical concern of greater epithelial vulnerability of colorectal mucosa compared to cervicovaginal mucosa. It is not hard to imagine that loss of the epithelial lining would increase the risk of HIV infection, although this has not been proven. When more subtle alterations in colorectal physiology and function were later noted in clinical rectal microbicide studies-including cytokine expression, permeability, proteomics, and HIV infectivity of tissue explantsit remains challenging to interpret these theoretical toxicity signals in the absence of knowing their impact on HIV seroconversion.
SYSTEMIC OR MUCOSAL PROTECTION
Essential, yet unresolved, scientific questions for PrEP development include: what is the relevant site of PrEP drug actionsystemically circulating cells, mucosal tissue cells, somewhere in between like lymph nodes-and the target ARV concentration that confers protection. Several lines of empirical data support a relatively more important role for mucosal than systemic drug concentration, as most variation in outcomes is best explained by mucosal differences rather than systemic, as follows: sponse relationships across all of the primary RCTs using daily dosing, most of the variation in the relationship is explained by adjusting for anatomic differences of TFV-DP concentrations at mucosal sites of HIV acquisition and the higher RAI risk in MSM; both are mucosal differences, not systemic. 17 Ongoing RCTs of long-acting (LA) injectable cabotegravir (CAB; HPTN 083/084) and oral TAF/FTC (DISCOVER) may contribute greatly to understanding the relative importance of systemic and mucosal drug concentrations; both CAB and TAF have much lower mucosal tissue concentrations compared with their systemic concentrations, whereas their RCT comparator, TDF, achieves higher mucosal (cervicovaginal and, especially, colorectal) than systemic concentrations. 92, 93 If mucosal tissue concentration is dominant, as the evidence above indirectly suggests, then topical products with far higher mucosal tissue concentrations remain viable formulation options for expanding PrEP choices.
Based on our efficacy eroding variables list, the focus for new product development should shift to: designing products that maximize adherence, developing products that protect both vaginal and rectal infection or can be applied to both locations, selecting only research participants whose route of infection aligns with the product studied, and rigorously diagnosing and treating bacterial vaginosis (when relevant for a specific drug, like vaginally dosed TFV). For example, on-demand behaviorally congruent rectal microbicide trials in MSM and TGW will avoid most of these issues if adherence is high (as it increasingly has been since iPrEx and should continue to be with behaviorally congruent formulations). Trials of the same rectal microbicides in women could enroll only women who do not practice RAI (a challenge, especially in high-risk commercial sex settings). Alternatively, trials of promising vaginal microbicide candidates (if not demonstrating good vaginal to rectal penetration) could include effective rectal microbicides for all women to have RAI to protect those who need them and to remove anal sex as a variable contributing to reduced vaginal PREP efficacy.
LAST AND NEXT GENERATION TFV MICROBICIDE DEVELOPMENT Early vaginal TFV gel development
The development path for the TFV 1% vaginal formulation (termed VF to distinguish it from later formulations) moved through clinical development to RCTs with very few preliminary studies ( Figure 2, top right) . The phase I PK evaluation (HPTN 050) was completed without the benefit of single or multiple ascending dose evaluations. The phase II extended safety study (HPTN 059) was completed without proof-of-concept (explained above) and development moved into three pivotal phase III RCTs (on-demand dosing in CAPRISA 004, FACTS 001 intended to be the confirmatory test, and daily dosing in VOICE). 7, 11, 12, 94, 95 VF development did not have the advantage of prior TFV gel treatment trials demonstrating efficacy, well-described multiple anatomic compartment PK, knowledge of HIV distribution or tissue PK impact of semen within the female genital tract after sex, viral challenge studies (macaque, bone marrow liver thymic (BLT) mouse, or ex vivo explant with in vivo dosing) prior to phase III vaginal gel efficacy studies (although all were available after or in parallel with vaginal gel RCTs). 53, 61, 67, [96] [97] [98] [99] There are no published examples of iterative product optimization or comparisons to select from among competing TFV gel candidates. In the phase II safety trial, HPTN 059, soft signals of VF product limitations appeared (e.g., a minority of participants liked the product or found it easy to use) that might have led to development of a more agreeable formulation. 95 Assuming those symptoms might have impacted product adherence, investigators had only self-reported adherence to help interpret the findings absent objective adherence measures either not used (electronic monitoring system) or not yet developed (drug concentrations). These VF trials were much of the impetus to develop quantitative PrEP-specific adherence measures to detect and improve adherence. Only in the aftermath of the TFV gel trials that did not show protection were these early signals better understood as possibly clinically significant. This is not unlike unvalidated toxicity signals seen in early non-ARV vaginal microbicide development whose impact became clearer after subsequent large trials demonstrated enhanced risk of HIV infection.
Rectal microbicide demand
Initiation of rectal microbicide development lagged years behind vaginal microbicide development. Rectal microbicides are in demand as alternatives to oral PrEP due to the very high risk of unprotected RAI in MSM and TGW as well as significant minorities of MSM and TGW (27% in MTN-017) indicating oral daily TDF/FTC as their least preferred regimen (compared to on-demand and daily gel regimens); these participants also indicated displeasure with the rectal gel applicator in the gel arms of the study. 100 Important numbers of MSM and TGW struggle to maintain adherence on PrEP as, for example, most of PrEP demonstration project failures are in persons without detectable ARVs in their blood. MSM and TGW advocates and community level discussions have long indicated a high level of interest for on-demand, behaviorally congruent PrEP with lubricants or anal douches. Proof-of-concept for on-demand strategies is supported by Ipergay's highly protective on-demand oral TDF/FTC regimen (86% relative risk reduction) and CAPRISA 004's on-demand VF gel achieving high levels of protection as well (73% relative risk reduction) when adherence was very high. 15, 76 Survey research indicates a large majority of MSM (85-95%) almost always use lubricants with anal sex and 67-80% always or almost always use rectal douches (enemas) prior to anal sex. 101 A recent online survey of 4,751 MSM conducted on Grindr, a popular gay dating application, indicated that among the 78% of respondents who had RAI in the past 3 months, 80% used a rectal douche before sex. Nearly all respondents who currently douche (98%) or do not douche (96%) indicated they would likely use an effective rectal microbicide; 95% of respondents practicing insertive anal sex indicated support of their receptive partners using a rectal microbicide douche. 102 Numerous studies of female sex workers, another highrisk group, also indicate high frequencies of sexual lubricant and vaginal douching use. Accordingly, lubricants and douches emerge as desirable candidates for addition of ARV to piggy-back HIV protection onto existing sexual product use.
Rectal method development
Because microbicide products for rectal use followed years after the start of the TFV vaginal gel program, rectal development benefited not only from the lessons of vaginal microbicide development, but also from many clinical, preclinical, and laboratory methods that greatly enabled quantitative, comparative, and iterative assessments of rectal microbicide candidates against a desired target product profile. These methods (Figure 2 , left panel) included mucosal tissue CD4+ T cell intracellular pharmacology, imaging studies of gel and semen distribution in the lower GI tract, and noninvasive toxicity assessment using gut permeability. 48, 49, [68] [69] [70] 79 Preclinical BLT and NHP models greatly matured during this time as well as the ex vivo explant challenge model, and all of them indicated rectal TFV gels conferred rectal protection (Data S1). Acceptability assessments tailored to implementation in short, limited drug exposure studies, using "take home" doses for use with sex partners and in mano evaluations to explore tactile experiences with the products were implemented, refined, and Figure 2 Comparison of the vaginal tenofovir (TFV) and rectal TFV microbicide product development pathways. Left column indicates numerous methods developed primarily to enhance rectal product development, which later influenced vaginal product development, but not in a timely way for TFV 1% vaginal gel development. Four different TFV microbicide products (middle text indicating vaginal formulation (VF), reduced glycerin vaginal formulation (RGVF), rectal formulation (RF), and enema formulation (EF)) were developed in temporal sequence (top to bottom). The traditional development stages for both vaginal (top, tan boxes) and rectal (lower, blue boxes) include a brief list of design elements for pharmacokinetic (PK), safety, and acceptability becoming increasingly complex. Red boxes indicate development "no go" decisions. Blue outlined boxes indicate needed future studies to advance rectal microbicide products. AE, adverse event; GI/GYN, gastrointestinal/gynecological; HIV, human immunodeficiency virus; MAD, multiple ascending dose study; PK, pharmacokinetic; PD, pharmacodynamic; RCT, randomized controlled trial; SAD, single ascending dose study.
STATE of the ART applied in first-in-human vehicle and medicated product studies. 51, 58, 59 Although some of these methods were specific to rectal microbicide development, many were also highly informative for parallel development of vaginal products.
Rectal TFV gel development
The first clinical study of rectal TFV, RMP-02/MTN-006 (Anton Microbicide Development Program within the IP/CP-HTM Program collaborating with MTN), used the hyperosmolar VF formulation (3,111 mOsm/kg) in parallel with the study of VF in CAPRISA 004 and VOICE. Previously, rabbit rectal irritation studies indicated no toxicities with the gel and the gel protected six of nine macaques from rectal SHIV challenge. 103 As was true for all rectal product studies that followed, RMP-02/MTN-006 included a wider array of safety and PK assessments than vaginal TFV gel studies at similar stages of development, largely because more methods were now available. 51 In only 30 minutes, a single rectal dose of VF achieved impressive rectal tissue cell TFV-DP concentrations sixfold greater than steady-state concentrations associated with oral dosing, which achieved high levels of protection. 51 However, lower GI symptoms after VF rectal dosing, which was attributed to the hyperosmolar gel, ended development of VF for rectal use.
The combination of adverse events associated with hyperosmolar VF (RMP-02/MTN-006) and earlier studies of hyperosmolar sexual lubricants and enemas causing loss of colorectal epithelial cells led to development of reduced glycerin vaginal formulation (RGVF) with lower, but still hyperosmolar, characteristics (836 mOsm/kg). 58, 79, 104 Phase I MTN-007 demonstrated a clean side effect profile for RGVF of TFV. 105 In an extended safety and acceptability study of the RGVF gel applied rectally, MTN-017, side effects remained very low, adherence very high, and on-demand dosing of the gel was preferred to daily gel dosing. 25 Participants were not so enamored of the rectal gel applicator, borrowed from the vaginal development program, and consensus among investigators was that applicator dosing would not be acceptable in extended RCTs. 41 ,100 MTN-014 demonstrated poor penetration of TFV into vaginal tissue after rectal RGVF dosing, indicating a future TFV rectal product applied rectally would not likely perform well protecting vaginal HIV infection. 78 In parallel with the RGVF studies and out of concern for hyperosmolar toxicity, interest grew in an iso-osmolar rectal optimized gel. A head-to-head clinical study of four different iso-osmolar nonmedicated rectal semisolid and liquid vehicles, developed by Wang et al., indicated a clearly superior formulation based on high levels of acceptability, including use during anal sex at home, GI distribution, safety, and ex vivo explant protection even without adding an ARV. 59, 106 This vehicle was modified to accommodate addition of 1% TFV in a more nearly iso-osmolar (479 mOsm/ kg) rectal formulation, named RF. CHARM 01 and CHARM 02 directly compared the three TFV 1% formulations (VF, RGVF, and RF) applied rectally and found RF was superior to or equivalent to the other two formulations in all categories-PK, PD, acceptability, and safety. 62, 71 In these studies, RGVF achieved higher tissue TFV-DP concentrations than RF, but performed slightly less well than RF in the ex vivo explant HIV challenge, raising concern that local toxicity with the hyperosmolar RGVF may have eroded its protective effect compared to the more nearly iso-osmolar RF-possibly a bell-shaped efficacy curve. At this point, neither RGVF nor the vaginal applicator has plans for advancement to efficacy studies. Although the more promising RF remains viable, it needs a method to deliver a dose rectally given the displeasure with the applicator developed for vaginal use uncovered in MTN-017.
Lubricant formulation development
RF gel would be a strong candidate for a medicated anal lubricant microbicide. Lubricant doubling as microbicide provides an ondemand, behaviorally congruent option, has long been sought by the gay community, and solves the vaginal applicator acceptability problem. However, study of an over-the-counter anal lubricant (Wet Original, Trigg Laboratories, Inc. Las Vegas, NV), radiolabeled and applied as a lubricant with only fingers and phallus, indicate highly inefficient (< 10%) intrarectal dose delivery (as seen on SPECT/ CT) compared to use of a gel applicator. 72 Ongoing MTN-033 evaluates the colorectal tissue distribution of DPV gel applied as an anal lubricant with results expected in 2019. Future development of anal lubricants as microbicide depends greatly on this study.
Enema formulation development
An ARV-medicated enema as rectal douche before anal sex also provides an on-demand, behaviorally congruent rectal microbicide option. In parallel with rectal gel development, another Anton Microbicide Development Program study demonstrated the safety and desired colonic distribution of an iso-osmolar douche that avoided the significant toxicity of a hyperosmolar Fleet enema and performed well as a douche in sexual settings. 58 A TFV hypoosmolar enema formulation (EF) has emerged from an optimization program in mice and macaques into clinical development (DREAM IP/CP-HTM Program). 107, 108 Xiao et al., 109 demonstrated an EF dose 1 hour prior to weekly SHIV rectal challenge in macaques confers high levels of protection (5 of 6 macaques) when compared to daily oral TDF dosing (3 of 6 protected). In a clinical single ascending dose study (DREAM-01), EF achieved colorectal cell TFV-DP concentrations 1-3 hours after a single douche that exceed by 100 to 1,000-fold the steady-state protective concentrations achieved with oral TDF, suppresses HIV infection in ex vivo explants, and maintains a high degree of acceptability and safety. 110 Imaging studies to evaluate coincident EF and semen colorectal distribution following simulated RAI (DREAM-02) and multiple douches in rapid sequence, more consistent with typical pre-RAI douching practice (DREAM-03), are planned for 2019. Clinical trial simulation to optimize phase III clinical trials are currently underway building upon existing adherence, PK, and viral dynamics models.
NEXT GENERATION ARV PREP STRATEGIES
Improving adherence drives next generation PrEP innovation and can be categorized by two major contrasts: (1) long-acting vs. shortacting and (2) systemic vs. local application (further differentiated into vaginal or rectal). Strategic categories of pipeline products are summarized in Table 4 with regard to how they stack up to the eight PrEP development challenges discussed above. A select list of numerous ARV PrEP products in clinical development within these categories (Table 5 ) encourages the hope that new product choices, suited to a broader range of individual needs, will prevent infections more broadly. At the intersection of PrEP and contraception, at least eight multipurpose prevention technologies (MPTs), designed to prevent HIV and pregnancy in a single product, are currently in varied stages of development. One long-acting MPT development challenge worth noting is the complexity of differing release rates and subsequent PKs of ARV and contraceptive from the same product vehicle. MPT trial design is further complicated by multiple primary prevention outcomes, each with different incidence rates. Product and trial optimization usually requires de-optimization of two individual drug formulations or trial designs to accommodate the multiple MPT goals.
Short-acting local
The most extensively tested short-acting local PrEP products are the vaginal and rectal TFV microbicides contrasted above where the rationale and proof-of-concept evidence for on-demand strategies was discussed. Struggles with oral dosing adherence, desire to avoid systemic side effects, or preference for more behaviorally congruent formulations that fit seamlessly within sexual behaviors drive demand for vaginal and rectal formulations. The behavioral congruence is highly attractive because it does not require the adoption of new medicating behaviors. Rather, it only requires typical use of products already commonly used, but which have been enhanced by addition of effective ARVs.
Vaginal pipeline. The goal of most of these development programs is improved adherence through simpler, optimally on-demand use, and possibly behaviorally congruent use as a vagina lubricant or douche. Ondemand formulations in clinical development include TFV and DPV fast-dissolving films similar to over-the-counter vaginal contraceptive films (Hillier's FAME IP/CP-HTM Program). Both the DPV film and TFV film performed similarly to the comparator gels. Single dose films achieved concentrations near or above steady-state concentrations with the DPV IVR and TDF oral dosing, respectively, indicating potential for on-demand use. 56, 57, 60, 61 CONRAD and MTN are co-developing TFV/elvitegravir combinations as a vaginal (and rectal) fast-dissolve insert for on-demand use.
Rectal pipeline. At present, six ARVs (three approved for treatment (TFV, elvitegravir, and maraviroc) and three others (DPV, MIV-150, and IQP-0528) in four different dosing formulations (gel with applicator, gel as lubricant, douche, and fast-dissolving insert) have recently or will soon be studied in clinical PK and safety studies. Griffithsin and 5P12-RANTES bind HIV in the colorectal lumen and are nearing clinical development. Among these products, there may be candidates that could meet the needs of an on-demand and behaviorally congruent formulation, overcome the two sites of risk protection need, or serve as STATE of the ART MPT with activity against HIV and other viruses (PC-1005) or could be suitable for coformulation as MPT with other agents. The challenge with so many options will be deciding from among competing candidates and developing more user-friendly formulations for ondemand application that avoid or improve upon past applicator designs.
Long-acting local
The monthly DPV IVR is currently under EMA review. Rings containing DPV, TFV, TDF, MVC, or FTC alone or in combination using matrix, reservoir, and pod-IVR configurations are also in clinical development. As mentioned, the pod-IVR design achieved potentially protective concentrations of FTC and MVC in rectal fluid, possibly solving the two sites of infection-one site of application problems. 80 An MPT IVR combining DPV and levonorgestrel designed to last 90 days achieved safety and drug concentration targets in a 14-day clinical study (MTN-030/ IPM041). 111 A 90-day ring study is ongoing (MTN-044).
Short-acting systemic
Oral. Gilead is competing their oral daily TAF/FTC fixed dose combination head-to-head against their highly effective oral daily TDF/FTC PrEP in a double-blind, randomized trial, DISCOVER. In combination with other ARVs, TAF proved effective in the HIV treatment setting and has greater potency due to more efficient penetration of susceptible CD4+ T cells in blood with intracellular transformation of TAF into TFV by cathepsin A. TAF/FTC, but not TAF alone, proved highly effective in NHP challenge studies, but has not been tested in BLT mouse or ex vivo HIV challenge studies. One potentially important difference between TAF and TDF in DISCOVER is that TDF may achieve higher TFV-DP concentrations than TAF in cervicovaginal and colorectal cells (Table 3) .
93,112
Cathepsin A is differentially expressed anatomically and may be the cause of this difference. The clinical importance depends on both the contribution of FTC and the relative importance of systemic vs. mucosal ARV concentrations, as discussed above. The superior PK characteristics consistent with weekly oral dosing of Merck's EFdA make it a strong future competitor of the TFV prodrugs. 
Long-acting systemic
Injectables. In the 1950s, adding benzathine turned penicillin's 30 minute half-life into a 336-hour effective half-life long-acting (LA) injectable. The LA injectable contraceptive depot medroxyprogesterone acetate is dosed i.m. quarterly due to a 30-day effective half-life. Depot medroxyprogesterone acetate also provides useful lessons for LA PrEP development. Using different nanoformulation methods, LA rilpivirine (RPV-LA), a non-nucleoside reverse transcriptase inhibitor, and CAB-LA, an integrase strand transfer inhibitor, are paired in phase III development for HIV treatment. RPV-LA is not being pursued further for PrEP, likely due to several challenges: low barrier to resistance, cold chain requirement, and lower mucosal tissue RPV concentrations compared to blood. CAB-LA is a low solubility nanomilled crystalline drug suspended in an aqueous vehicle and avoids several RPV-LA limitations (higher resistance barrier and no cold chain). Using bimonthly i.m. injections, CAB-LA is being compared to daily oral TDF/ FTC in two phase III RCTs. In an abundance of caution, a 1-month oral CAB lead-in is being used to rule out side effects before the first LA injection. Because of concern for antiviral resistance due to persistence of CAB in the blood after dosing stops (over a year in a significant number of research participants), cessation of CAB-LA dosing is followed by 48 weeks of daily oral TDF/FTC. These leading and trailing oral requirements are challenges in light of CAB-LA's principle role to avoid daily oral PrEP dosing. In the phase II safety studies, injection site reactions were common, but mostly minor with few related discontinuations. 114, 115 Although outside our small molecule ARVs focus, LA injectable formulations of broadly neutralizing monoclonal antibodies (bnMAbs) are in advanced clinical development. Rare HIV-infected "elite" neutralizers evolve neutralizing antibodies naturally and serve as the basis for engineering more broadly neutralizing, more potent, and longer half-life antibodies. These antibodies both neutralize envelope and recruit effector cells to kill HIV infected cells. The bnMAbs protect macaques from rectal SHIV challenge. 116 The phase IIb Antibody Mediated Prevention (AMP) study (HVTN 074/HPTN 085) is now enrolling 2,700 MSM and TGW to receive VRC01 or placebo in bimonthly i.v. infusions for 72 weeks. AMP's placebo-controlled design is quite unlike the HPTN 083/084 and DISCOVER studies, which compare CAB-LA and TAF/FTC, respectively, head-to-head with standard of care oral TDF/FTC. In contrast, AMP assures oral TDF/FTC availability to all study participants at no charge, although outside the study. Numerous other bnMAbs in less advanced clinical development boast broader, more potent, and longer half-life profiles with promise for less frequent subcutaneous dosing and greater efficacy.
Implantable. Subcutaneously implanted devices, designed to very slowly release ARVs over months or years, would dramatically extend PrEP duration, avoid adherence challenges, and greatly reduce 117 healthcare system interactions. Several groups have reservoir (TAF and CAB) and matrix (EFdA) implants in preclinical development, some with promise for yearly implants in humans. [118] [119] [120] In particular, EFdA, a nucleoside reverse transcriptase translocation inhibitor, is very well suited for implantation with sub-nM antiviral potency and longer intracellular triphosphate half-life than even TFV-DP. EFdA protects macaques from SHIV challenge with daily or weekly dosing. 113 These implant programs typically use existing contraceptive implant trocars obviating the need for additional device development. Some groups are exploring biodegradable devices that trade off a removal procedure with the design challenge of optimizing drug release and device degradation rates to minimize multiple simultaneously indwelling devices as they degrade.
CONCLUSION
The development of highly effective oral TDF/FTC as PrEP has led to impressive and rapid population level reductions in HIV incidence among MSM. PrEP efficacy in women has been less impactful due to poor adherence and other issues specific to women. These limitations reinforce the need for improved PrEP formulations that provide a choice of effective options suited to heterogeneous individual needs in the very complex intersection of sexual intimacy and HIV risk. Clinical pharmacology has been fruitfully engaged as an essential discipline to develop novel quantitative PK and PD assessments unique to PrEP development, guide early clinical development, and to optimize future trial design through modeling and simulation. The current PrEP pipeline is rich with early-stage products in a wide variety of ARV and formulation options, which align with the needs and desires of people who are most in need of PrEP. The combination of unmet PrEP product need, waning governmental support, successful PrEP development examples, and clear evidence of markets and state level support for PrEP programs should further encourage public-private industry partnerships to accelerate further PrEP development. Data S1. Non-human and ex vivo tissue challenge models.
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